

# Certificate of Analysis for NR-55332

## SARS-Related Coronavirus 2, Isolate hCoV-19/USA/CA-CDC-50070/2020 (Lineage B.1.429)

## Catalog No. NR-55332

## **Product Description:**

Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate hCoV-19/USA/CA-CDC-50070/2020 was isolated from a nasopharyngeal aspirate in California, USA on December 23, 2020. NR-55332 lot 70043179 was produced by infecting *Homo sapiens* lung adenocarcinoma cells (Calu-3; ATCC® HTB-55™) with the deposited material and incubating in Eagle's Minimum Essential Medium (ATCC® 30-2003™) supplemented with 2% fetal bovine serum (ATCC® 30-2020™) for 3 days at 37°C with 5% CO₂. The cells and supernatant were spin-clarified at 1500 × g for 10 minutes at 4°C.

### Passage History:

V(2)/C(1) (Centers for Disease Control and Prevention/BEI Resources); V = Cercopithecus aethiops kidney cells; C = Calu-3 cells

Lot: 70043179 Manufacturing Date: 22MAR2021

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <a href="mailto:Contact@BEIResources.org">Contact@BEIResources.org</a>. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS	
Identification by Infectivity in Calu-3 Cells	Cell rounding and detachment	Cell rounding and detachment	
Next-Generation Sequencing (NGS) of Complete Genome Using Illumina® iSeq™ 100 Platform (Refer to Appendix I for NGS information)	≥ 98% identity with SARS-CoV-2, hCoV-19/USA/CA-CDC- 50070/2020 (GISAID: EPI_ISL_1225966)	100% identity with SARS-CoV-2, hCoV-19/USA/CA-CDC- 50070/2020 (GISAID: EPI_ISL_1225966)	
Titer by TCID <sub>50</sub> Assay in Calu-3 Cells by Cytopathic Effect <sup>1</sup> (6 days at 37°C and 5% CO <sub>2</sub> )	Report results	8.9 × 10 <sup>6</sup> TCID <sub>50</sub> per mL	
Sterility (21-day incubation)			
Harpo's HTYE broth, 37°C and 26°C, aerobic <sup>2</sup>	No growth	No growth	
Trypticase Soy broth, 37°C and 26°C, aerobic	No growth	No growth	
Sabouraud broth, 37°C and 26°C, aerobic	No growth	No growth	
Sheep blood agar, 37°C, aerobic	No growth	No growth	
Sheep blood agar, 37°C, anaerobic	No growth	No growth	
Thioglycollate broth, 37°C, anaerobic	No growth	No growth	
DMEM with 10% FBS, 37°C, aerobic	No growth	No growth	
Mycoplasma Contamination			
Agar and broth culture (14-day incubation at 37°C)	None detected	None detected	
DNA detection by PCR of extracted Test Article nucleic acid	None detected	None detected	

<sup>&</sup>lt;sup>1</sup>The Tissue Culture Infectious Dose 50% (TCID<sub>50</sub>) endpoint is the 50% infectious endpoint in cell culture. The TCID<sub>50</sub> is the dilution of virus that under the conditions of the assay can be expected to infect 50% of the culture vessels inoculated, just as a Lethal Dose 50% (LD<sub>50</sub>) is expected to kill half of the animals exposed. A reciprocal of the dilution required to yield the TCID<sub>50</sub> provides a measure of the titer (or infectivity) of a virus preparation. <sup>2</sup>Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

### /Heather Couch/

Heather Couch 14 OCT 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



# Certificate of Analysis for NR-55332

#### APPENDIX I: NGS Information for NR-55332 lot 70043179

Sequence analysis using SBC v2.0 pipeline and freebayes v1.3.1 variant caller resulted in the discovery of one SNP when compared to the reference sequence from GISAID EPI\_ISL\_1225966 (see Table I below). Additionally, both the reference sequence EPI\_ISL\_1225966 and NR-55332 lot 70043179 contained twenty-six SNPs when compared to GenBank MN908947 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome) (see Table II below). Quality scores over 60 indicate it is improbable that the variant call is incorrect.

Table I: Variants with different nucleotides between NR-55332 lot 70043179 and reference sequence EPI\_ISL\_1225966

Variant Type	Variant Position and Identified Alternative Base	Coverage	Length of Variant	Frequency of Variant	Gene (Region)	Amino Acid Mutation
SNP	a25201g	1287	1	5.3613%	Spike	Silent mutation

Table II: Variants with different nucleotides between NR-55332 lot 70043179 and GenBank MN908947.3 (SARS-CoV-2, isolate Wuhan-Hu-1, complete genome)

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	c241t	N/A	1	100.0000%	5'UTR	Untranslated
SNP	c1059t	N/A	1	100.0000%	ORF1ab (nsp2)	T85I
SNP	c1912t	N/A	1	100.0000%	ORF1ab (nsp2)	Silent mutation
SNP	c2395t	N/A	1	100.0000%	ORF1ab (nsp2)	Silent mutation
SNP	t2597c	N/A	1	100.0000%	ORF1ab (nsp2)	Silent mutation
SNP	c3037t	N/A	1	100.0000%	ORF1ab (nsp3)	Silent mutation
SNP	c8947t	N/A	1	100.0000%	ORF1ab (nsp4)	Silent mutation
SNP	c12100t	N/A	1	100.0000%	ORF1ab (nsp8)	Silent mutation
SNP	a12878g	N/A	1	100.0000%	ORF1ab (nsp9)	I65V
SNP	c14408t	N/A	1	100.0000%	ORF1ab (nsp12)	P323L
SNP	g17014t	N/A	1	100.0000%	ORF1ab (nsp13)	D260Y
SNP	g21600t	N/A	1	100.0000%	Spike	S13I
SNP	g22018t	N/A	1	100.0000%	Spike	W152C
SNP	t22917g	N/A	1	100.0000%	Spike	L452R
SNP	a23403g	N/A	1	100.0000%	Spike	D614G
SNP	t24349c	N/A	1	100.0000%	Spike	Silent mutation
SNP	g25563t	N/A	1	100.0000%	ORF3a	Q57H
SNP	c26681t	N/A	1	100.0000%	Membrane protein	Silent mutation
SNP	g27459t	N/A	1	100.0000%	ORF7a	E22D
SNP	c27513t	N/A	1	100.0000%	ORF7a	Silent mutation
SNP	c27879t	N/A	1	100.0000%	ORF7b	H42Y
SNP	g27890t	N/A	1	100.0000%	Intergenic (ORF7b/ORF8)	Untranslated
SNP	a28272t	N/A	1	100.0000%	Intergenic (ORF8/ Nucleocapsid)	Untranslated
SNP	g28845a	N/A	1	100.0000%	Nucleocapsid	R191H
SNP	c28887t	N/A	1	100.0000%	Nucleocapsid	T205I

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



# **Certificate of Analysis for NR-55332**

Variant Type	Variant Position and Identified Alternative Base	Coverage <sup>1</sup>	Length of Variant	Frequency of Variant <sup>1</sup>	Gene (Region)	Amino Acid Mutation
SNP	c29362t	N/A	1	100.0000%	Nucleocapsid	Silent mutation

<sup>&</sup>lt;sup>1</sup>Coverage for all variants in Table II is listed as 'N/A'. There is no read coverage information for these variants because the sample reads are only mapped to the reference sequence and not to the SARS-CoV-2, Wuhan-Hu-1 isolate sequence (GenBank MN908947), but that does not mean these areas lack for coverage. All variants in Table II are mismatches in between the reference sequence and the SARS-CoV-2, Wuhan-Hu-1 sequence, so these variants will be assigned a frequency of 100% and will therefore be majority SNPs.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898